Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR7148(2)(B)] to Loricrin
- Suitable for: IHC-P, WB
- Reacts with: Human
Product nameAnti-Loricrin antibody [EPR7148(2)(B)]
See all Loricrin primary antibodies
DescriptionRabbit monoclonal [EPR7148(2)(B)] to Loricrin
Tested applicationsSuitable for: IHC-P, WBmore details
Unsuitable for: ICC or IP
Species reactivityReacts with: Human
Synthetic peptide within Human Loricrin aa 1-100. The exact sequence is proprietary.
Database link: P23490
- Human skin lysate and Human skin tissue.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab176322 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-P||1/250 - 1/500. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.|
|WB||1/10000 - 1/50000. Predicted molecular weight: 26 kDa.|
FunctionMajor keratinocyte cell envelope protein.
Involvement in diseaseDefects in LOR are a cause of progressive symmetric erythrokeratodermia (PSEK) [MIM:133200]. Erythrokeratodermas are a group of disorders characterized by widespread erythematous plaques, either stationary or migratory, associated with features that include palmoplantar keratoderma. PSEK is characterized by erythematous and hyperkeratotic plaques.
Defects in LOR are the cause of Vohwinkel syndrome with ichthyosis (VSI) [MIM:604117]; also known as loricrin keratoderma (LK) or mutilating keratoderma with ichthyosis. VSI is an ichthyotic variant of Vohwinkel syndrome (VS) characterized by progressive symmetric erythrokeratoderma or congenital ichthyosiform erythroderma born as a collodion baby. Common clinical features include hyperkeratosis of the palms and soles with digital constriction.
modificationsSubstrate of transglutaminases. Some glutamines and lysines are cross-linked to other loricrin molecules and to SPRRs proteins.
Contains inter- or intramolecular disulfide-bonds.
Cellular localizationCytoplasm. Nucleus > nucleoplasm.
- Information by UniProt
- LOR antibody
- LOR protein antibody
- LORI_HUMAN antibody
Anti-Loricrin antibody [EPR7148(2)(B)] (ab176322) at 1/10000 dilution + Human skin lysate at 10 µg
Predicted band size: 26 kDa
Immunohistochemical analysis of paraffin-embedded Human skin tissue labeling Loricrin using ab176322 at a 1/250 dilution.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
ab176322 has been referenced in 2 publications.
- Tan CL et al. Nicotinamide Metabolism Modulates the Proliferation/Differentiation Balance and Senescence of Human Primary Keratinocytes. J Invest Dermatol 139:1638-1647.e3 (2019). PubMed: 30776433
- Tang Y et al. RNF31 Regulates Skin Homeostasis by Protecting Epidermal Keratinocytes from Cell Death. J Immunol 200:4117-4124 (2018). PubMed: 29728512